catalyst
as of 2026-07-01Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resista — primary completion
at a glance
2027-02 · Estimated (est.) — Registry-estimated date, not yet actual.
Synthesized from structured facts only — each point cited above.
Event
What
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resista — primary completion
Type
Trial Readout
Date
2027-02
Date type
ESTIMATED est.
Phase
Phase 2
Registry-estimated date, not yet actual. This date is directional and must not be read as settled.
relationships
The graph out of here